Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Rough US Stock Market Doesn't Stop Biopharma IPOs As Six More Go Public

Executive Summary

October has not been kind to biotech stocks, but that hasn't stopped drug developers from launching IPOs in the US. Also, Takeda reconfigures debt ahead of Shire deal and other offerings.

Advertisement

Related Content

Deal Watch, Licensing & Alliances: Amgen Places $66m Bet On Genetic Sequencing
Finance Watch: With The Year's Biggest IPO, CFO Says Allogene Is Ready To Go 'Full Throttle'
Orchard Cash Pile Set To Rise With Nasdaq IPO
Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising
Finance Watch: Three New Funds, Including Former Amgen R&D Head Harper's Next Venture
IPO Update: August Had A Slow Start, But New US Filings Hint At Busy September
Finance Watch: Regulus Shrinks To Preserve Cash, Ironwood Cuts Jobs Ahead Of Split
Takeda Grabs Shire At Last After Long Pursuit
Venture Funding Deals: MedImmune Spinout Viela Lands $250m Series A
Finance Watch: Mysterious Gossamer Raises $100m As VC Deals Surge Ahead of J.P. Morgan

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124095

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel